戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ally compared with the achievements in adult psychopharmacology.
2 sorders and open an exciting new frontier in psychopharmacology.
3 argeting this mechanism might be feasible in psychopharmacology.
4 ogenetic/pharmacogenomic (PGx) approaches to psychopharmacology aim to identify clinically meaningful
5 asurements, which we hope to validate, using psychopharmacology and studies of schizophrenia.
6 the major obstacles to research in pediatric psychopharmacology and to propose feasible solutions.
7 a stand-alone option, or in combination with psychopharmacology and/or psychotherapy.
8 mized to a stepped combined care management, psychopharmacology, and cognitive behavioral psychothera
9 te associations of sociodemographic factors, psychopharmacology, and comorbidities with response.
10 ndings from a century of work in psychology, psychopharmacology, and neuroscience converge on the not
11  the scientific literature and the future of psychopharmacology, both from a clinical and methodologi
12 t a potential avenue to develop new GABA(A)R psychopharmacology by targeting these receptor-associate
13                       Both psychotherapy and psychopharmacology can be important adjunctive treatment
14 c diagnosis of the patients participating in psychopharmacology clinical trials.
15 dition, advances in imaging, immunology, and psychopharmacology have paved the way for using measures
16 est that both 1 and 3 would possess LSD-like psychopharmacology in humans.
17                                              Psychopharmacology is effective in reducing symptoms of
18 inciding with a period of major discovery in psychopharmacology), it is generally regarded as the qui
19               In behavioral neuroscience and psychopharmacology, linear models are frequently applied
20   Aggressive tendencies may be linked to the psychopharmacology of cocaine, yet few experimental appr
21 seful tool for studying the neurobiology and psychopharmacology of fear and anxiety.
22  of 5-HT(2A) Gq-efficacy in psychedelic-like psychopharmacology permits rational development of non-p
23 purpose of this American Society of Clinical Psychopharmacology-sponsored meeting was to identify str
24 the development of biological psychiatry and psychopharmacology than work on any other neurotransmitt
25 m into widespread use at the birth of modern psychopharmacology, that medication remains a mainstay f
26  how to combine psychosocial treatments with psychopharmacology to optimize treatment outcomes.
27 cians trained to administer psychotherapy or psychopharmacology to outpatients with PNES.
28 nly dealt with phenomenology/epidemiology or psychopharmacology, used low levels of technology, and w